Hydroxychloroquine Global Market Report 2026

Hydroxychloroquine refers to a quinolone-derived medication that is used to treat malaria. In countries or regions where it is recognized that other medications (such as chloroquine) may not be effective, it is also used to prevent malaria infection. In some hospitalized individuals, hydroxychloroquine may also be used to treat COVID-19 (COVID-19).

The main types of drug activities in hydroxychloroquine are anti-malarial, anti-rheumatic, lupus suppressant, anti-COVID-19, and others. Antimalarial drugs, or simply 'antimalarials,' are antiparasitic chemical agents that can be utilized to cure or prevent malaria. They are generally organically sourced. The different formulations include tablets, and injections and are used in malaria, rheumatoid arthritis, lupus erythematosus, COVID-19, and others. It is distributed through various channels such as hospital pharmacies, online pharmacies, specialty drug stores, and retail pharmacies.

Tariffs have impacted the hydroxychloroquine market by increasing the cost of imported raw materials and finished drug products, affecting supply chains and pricing across global markets. Segments like anti-malarial and anti-COVID-19 drugs are particularly affected, with regions such as North America, Europe, and Asia-Pacific seeing the highest impact due to import dependencies. While tariffs have increased costs and slowed distribution, they have also encouraged local production, investment in domestic pharmaceutical manufacturing, and development of cost-effective alternatives.

The hydroxychloroquine market research report is one of a series of new reports from The Business Research Company that provides hydroxychloroquine market statistics, including hydroxychloroquine industry global market size, regional shares, competitors with a hydroxychloroquine market share, detailed hydroxychloroquine market segments, market trends and opportunities, and any further data you may need to thrive in the hydroxychloroquine industry. This hydroxychloroquine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hydroxychloroquine market size has grown strongly in recent years. It will grow from $2.38 billion in 2025 to $2.52 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to high prevalence of malaria in endemic regions, established use in autoimmune disorders, increasing awareness of hydroxychloroquine benefits, availability through hospital and retail pharmacies, growing clinical adoption for rheumatoid arthritis and lupus.

The hydroxychloroquine market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to research on covid-19 applications, development of new formulations and delivery methods, expansion of online pharmacy channels, increasing government health initiatives for malaria prevention, rising investments in clinical trials and off-label studies. Major trends in the forecast period include rising use of hydroxychloroquine for malaria prevention and treatment, increasing adoption in rheumatoid arthritis and lupus management, growth in off-label uses and clinical research for covid-19, expansion of tablet formulations and injectable variants, rising distribution through hospital, online, and retail pharmacies.

The increasing incidence of rheumatoid arthritis is expected to drive the growth of the hydroxychloroquine market in the coming years. Rheumatoid arthritis is an autoimmune and inflammatory disorder in which the immune system mistakenly attacks healthy cells, resulting in inflammation in the affected areas of the body. Hydroxychloroquine plays an important role in the management of rheumatoid arthritis by helping to reduce inflammation and relieve symptoms, thereby improving patients' overall quality of life. For example, in June 2023, according to the Centers for Disease Control and Prevention, a US-based health protection agency, around 54.4 million adults in the United States were diagnosed with arthritis, and this number is projected to increase to 78 million by 2040. Consequently, the rising number of rheumatoid arthritis cases is contributing to the growth of the hydroxychloroquine market.

The rise in healthcare expenditure is also expected to support the expansion of the hydroxychloroquine market. Healthcare expenditure refers to the total financial resources allocated by individuals, organizations, or governments toward health services and medical products. Growth in healthcare spending is driven by factors such as an aging population, the increasing prevalence of chronic diseases, advances in medical technologies, and higher expectations for quality care. Hydroxychloroquine can help mitigate rising healthcare costs by offering a relatively affordable treatment option for multiple conditions, potentially reducing dependence on more expensive therapies and interventions. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, total health expenditure in Canada was projected to reach $344 billion in 2023, representing a growth of 2.8% compared with the previous year. Therefore, increasing healthcare expenditure is further driving the growth of the hydroxychloroquine market.

In August 2023, Ipca Laboratories, an India-based pharmaceutical company, acquired Unichem for $0.118 billion. Through this acquisition, Ipca aims to strengthen its product portfolio and expand its market presence by leveraging Unichem's capabilities across multiple therapeutic areas, while also enhancing its research and development strengths. Unichem is an India-based pharmaceutical company engaged in the development, manufacturing, and marketing of a broad range of generic and branded medicines across various therapeutic segments.

Major companies operating in the hydroxychloroquine market are Bayer AG, Dr. Reddy's Laboratories Ltd., Zydus Group, Ipca Laboratories Ltd., Wallace Pharma, Teva Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis AG, Intas Pharmaceuticals Ltd., Lupin Limited, Shanghai Zhongxi Sanwei Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, Sandoz International GmbH, Cipla Limited, Shenhua Pharmaceutical Co. Ltd., Sanofi S.A., Macleod Pharmaceuticals Ltd., Laurus Labs, TAJ Pharmaceuticals, Wuhan Wuyao Pharmaceutical Co. Ltd., Concordia Healthcare, Pfizer Inc., Cadila Pharmaceuticals, Hetero Drugs Ltd., Jubilant Generics Limited, Alembic Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA Inc., Alkem Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Unichem Laboratories Ltd., Wockhardt Limited, Emcure Pharmaceuticals Ltd., Strides Pharma Science Ltd., Indoco Remedies Ltd.

North America was the largest region in the hydroxychloroquine market in 2025. Middle East is expected to be the fastest-growing region in the hydroxychloroquine market report. The regions covered in the hydroxychloroquine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hydroxychloroquine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hydroxychloroquine market consists of sales of plaquenil, antimalarials, and immunosuppressants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hydroxychloroquine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hydroxychloroquine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hydroxychloroquine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hydroxychloroquine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Activity: Anti-Malarial Drug; Anti-Rheumatic Drug; Lupus Suppressant Drug; Anti COVID-19 Drug; Other Drug Activity
• 2) By Formulation: Tablets; Injection
• 3) By Application: Malaria; Rheumatoid Arthritis; Lupus Erythematosus; COVID-19; Other Applications
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Specialty Drug Stores; Retail Pharmacy
• Subsegments:
• 1) By Anti-Malarial Drug: Treatment Of Malaria; Prophylaxis For Malaria
• 2) By Anti-Rheumatic Drug: Treatment Of Rheumatoid Arthritis; Treatment Of Juvenile Idiopathic Arthritis
• 3) By Lupus Suppressant Drug: Treatment Of Systemic Lupus Erythematosus
• 4) By Anti COVID-19 Drug: Treatment Of COVID-19 Symptoms
• 5) By Other Drug Activity: Treatment Of Other Autoimmune Disorders; Additional Off-label uses
• Companies Mentioned: Bayer AG; Dr. Reddy's Laboratories Ltd.; Zydus Group; Ipca Laboratories Ltd.; Wallace Pharma; Teva Pharmaceuticals Inc.; Mylan Pharmaceuticals Inc.; Novartis AG; Intas Pharmaceuticals Ltd.; Lupin Limited; Shanghai Zhongxi Sanwei Pharmaceutical Co. Ltd.; Torrent Pharmaceuticals Ltd.; Hikma Pharmaceuticals plc; Sandoz International GmbH; Cipla Limited; Shenhua Pharmaceutical Co. Ltd.; Sanofi S.A.; Macleod Pharmaceuticals Ltd.; Laurus Labs; TAJ Pharmaceuticals; Wuhan Wuyao Pharmaceutical Co. Ltd.; Concordia Healthcare; Pfizer Inc.; Cadila Pharmaceuticals; Hetero Drugs Ltd.; Jubilant Generics Limited; Alembic Pharmaceuticals Limited; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma USA Inc.; Alkem Laboratories Ltd.; Glenmark Pharmaceuticals Ltd.; Unichem Laboratories Ltd.; Wockhardt Limited; Emcure Pharmaceuticals Ltd.; Strides Pharma Science Ltd.; Indoco Remedies Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.